Cited by 111Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture

Mayne, Janice, Dewpura, Thilina, Raymond, Angela, Bernier, Lise, Cousins, Marion, Ooi, Teik Chye, Davignon, Jean, Seidah, Nabil G +2 more·2011·Clinical Chemistry

Abstract

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) is a polymorphic gene whose protein product regulates plasma LDL cholesterol (LDLC) concentrations by shuttling liver LDL receptors (LDLRs) for degradation. PCSK9 variants that cause a gain or loss of PCSK9 function are associated with hyper- or hypocholesterolemia, which increases or reduces the risk of cardiovascular disease, respectively. We studied the clinical and molecular characteristics of a novel PCSK9 loss-of-function sequence variant in a white French-Canadian family. METHODS: In vivo plasma and ex vivo secreted PCSK9 concentrations were measured with a commercial ELISA. We sequenced the PCSK9 exons for 15 members of a family, the proband of which exhibited very low plasma PCSK9 and LDLC concentrations. We then conducted a structure/function analysis of the novel PCSK9 variant in cell culture to identify its phenotypic basis. RESULTS: We identified a PCSK9 sequence variant in the French-Canadian family that produced the PCSK9 Q152H substitution. Family members carrying this variant had mean decreases in circulating PCSK9 and LDLC concentrations of 79% and 48%, respectively, compared with unrelated noncarriers (n=210). In cell culture, the proPCSK9-Q152H variant did not undergo efficient autocatalytic cleavage and was not secreted. Cells transiently transfected with PCSK9-Q152H cDNA had LDLR concentrations that were significantly higher than those of cells overproducing wild-type PCSK9 (PCSK9-WT). Cotransfection of PCSK9-Q152H and PCSK9-WT cDNAs produced a 78% decrease in the secreted PCSK9-WT protein compared with control cells. CONCLUSIONS: Collectively, our results demonstrate that the PCSK9-Q152H variant markedly lowers plasma PCSK9 and LDLC concentrations in heterozygous carriers via decreased autocatalytic processing and secretion, and hence, inactivity on the LDLR.

Integrity signals

Registry

Crossref · 10.1373/clinchem.2011.165191

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PCSK9 loss-of-function mutations are associated with a marked increase of hepatic LDLR levels and a significant decrease of plasma LDL cholesterol levels.

    “loss-of-function (LOF) mutations of PCSK9 are associated with a marked increase of hepatic LDLR levels and a significant decrease of plasma LDL cholesterol levels”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mayne, J., Dewpura, T., Raymond, A., Bernier, L., Cousins, M., Ooi, T. C., Davignon, J., Seidah, N. G., Mbikay, M., & Chrétien, M.
Affiliations
  • University of Ottawa (CA)
  • Montreal Clinical Research Institute (CA)
Corresponding author
  • Mayne, Janice
  • Chrétien, Michel
Venue
Clinical Chemistry
Published
2011-10-01
Volume
57
Issue
10
Pages
1415-1423
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2101979622
Cited by
111
References
2
Citations by year
2025: 2 · 2024: 2 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 10 · 2017: 7 · 2016: 13 · 2015: 10 · 2014: 15 · 2013: 12 · 2012: 6
FWCI
10.29
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • AstraZeneca
  • Richard and Edith Strauss Foundation
  • Fondation Jean-Louis Lévesque
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
PCSK9, loss-of-function mutations, LDL cholesterol, hypercholesterolemia, hypocholesterolemia, LDL receptor, protein secretion, autocatalytic processing, familial hypercholesterolemia, French-Canadian families, heterozygous carriers
MeSH terms
Proprotein Convertase 9, Adult, Aged, 80 and over, Cells, Cultured, Female, Heterozygote, Humans, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Serine Endopeptidases, Genetic Variation, Proprotein Convertases, White People, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review